Is There a Gold Lining Among These Clouds?

Paper Gold, Physical Gold, and Miners

(Note: companies that
could be impacted by the content of this article are listed at the base of the
story [desktop version]. This article uses third-party references to provide a
bullish, bearish, and balanced point of view; sources are listed after the
Balanced section.)

When countries finance their way around a problem, they open the door to inflation. The current global “stay at home” economic environment has caused the U.S. and countries across the globe to find creative financing to help soften the financial burden on their citizens. In most cases, this involves “creating money.” Countries recently began creating money in many different forms, and they are creating a lot of it.

This increase in currency circulating means there is a much larger supply. Basic economics says when the supply of something goes up, unless it’s met with an equal increase in demand, its value goes down. In this case, the demand for what we purchase with cash is not expected to rise substantially. This could lead to a devaluing of currencies, which means it buys fewer goods and services. This is the definition of inflation.

During periods when the forecast of a currencies value is down, investors often hold a portion of their money in gold. This increased demand pushes gold prices higher. Therefore, when inflation remains high over a more extended period, there’s increased demand as gold becomes a tool to hedge against inflationary conditions.

We had seen this scenario begin to take place earlier this month and then reverse. According to a recent industry report by Noble Capital Markets, Inc., “ Year-to-date through March 23, the gold futures price increased 3.0% from $1,529.30 per ounce at year-end 2019 to finish at $1,575.55. During the same period, the Van Eck Vectors Gold Miners ETF (GDX) and Junior Gold Miners ETF (GDXJ) were down 25.1% and 35.9%, respectively, while the S&P 500 index was down 30.8%.” the report goes on to describe, “ On March 9, gold reached a high of $1,704.30 before reaching a low of $1,450.90 on March 16.”

Considering the monumental uncertainty in other asset classes, the continued low-interest rate environment, and inflationary ingredients, one would ordinarily expect gold to have not backed-off its March 9 highs. Some forecasts were for the metal to continue upward. The decline from its high has been attributed to institutional investors who held paper representing gold. This paper could include futures contracts, ETFs, or any other contractual certificate backed by physical gold. The traders were selling their paper to meet liquidity needs, reduce leverage in their portfolios, or take profits. Demand for gold actually was increasing, but there was a problem. The reason for physical gold to have dipped was likely the ability to physically deliver. Unlike wireable securities or shares in a fund, gold can’t be “zapped” into your account via any type of wire or electronic transmission. The problem with transacting in physical gold then is availability, finding it in the place, and the form, that the investor requires. All indications are that there is ample gold. The problem lies in buying a bar, or settling a futures contract with so many industries on lockdown; this created a new hurdle. Recent demand is up significantly, the Noble Report states, “Total U.S. Mint gold sales in March 2020 increased to 120,500 ounces compared with 7,000 ounces in February and 60,000 ounces in January.” Compared with the previous year, “In 2019, gold sales amounted to 65,000 ounces in January, 13,000 ounces in February, and 11,500 ounces in March.”  

A close up of a map

Description automatically generated

Although not back to it’s high,
gold (GDX as proxy) has rebounded as the stock market has
rebounded.

An article in Forbes magazine dated March 26, 2020, points out that the stocks of gold miners, which went down with the overall market, rather than track gold investments more closely, should rebound. “…the fact that the miners got crushed when gold didn’t is an unusual event and one that could be a useful moment for investors who want gold stocks in their portfolio.” There are two other considerations that investors who are looking at the mining sector should consider. ETFs of gold miners are designed to hold a broad array of companies, including some with operations shut down temporarily. Investors are forward-looking and should not necessarily shy away from companies presently idle due to CoVID-19; however, being aware of what is in any ETF is essential. An alternative is to develop a portfolio with individual stocks designed to minimize this issue. This may take more time plowing through research reports and company investor websites but may yield better results.

A close up of a map

Description automatically generated

The price swings of mining stocks (GDX-ETF) have been
more pronounced than gold itself.

For mining companies, an increase in gold prices translates to more revenue per ounce, at the same time lower fuel costs per ounce decreases production costs. In an economic environment with less noise, this would be considered very bullish for miners.

A close up of a map

Description automatically generated

Uncertainty leads to less interest in equities and a movement
toward safe harbor assets such as cash, gold, and US treasuries.

The price of gold and share price of companies mining precious metals have certainly not escaped volatility. As with other asset classes, the pandemic provides its own unique set of headwinds. At the same time, they do stand to benefit from talk of inflation and concern investors have surrounding the overall markets.

Long after the current turmoil is over, investors will have vivid memories of what could happen, they should consider owning gold investments as part of the core of their portfolio.

Suggested Reading:

What’s
going on with Gold

Current
Efforts to Combat Coronavirus Pandemic

Will
Interest Rates Test Negative for Coronavirus?

 

Sources:

What’s going on with Gold

Want
to buy gold coins or bars? Good luck finding any

Crushed Gold
Miners Could Be About To Shine

Research quotemedia qmci is it having trouble with the smaller fish while looking for a big one

Tuesday, March 31, 2020

QuoteMedia (QMCI)

Is It Having Trouble With The Smaller Fish While Looking For A Big One?

QuoteMedia, based in Fountain Hills, Arizona, provides cloud-based financial data, market news feeds, and financial software solutions.  Its customers include financial service companies, online brokerages, clearing firms, banks, media portals, public corporations and individual investors.  The company provides a single source solution providing products such as streaming quotes, charting, historical data, technical analysis, news and research.  Information can customized and provided to multiple platforms including terminals and mobile devices.

Michael Kupinski, DOR, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Uninspiring Q4. Revenues increased a moderate 4.3% to $2.97 million, a tad lighter than our $3.02 million estimate, or 6.1% growth. For the year, total company revenues increased 6.0%, a significant deceleration from full year 2018 revenue growth of 17.2%. Corporate and Individual Quotestream revenue weakness accounted for the muted revenue performance.

    Cash flow slightly better. Q4 cash flow, as measured by adjusted EBITDA, was $0.52 million, better than our…


    Click here to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Research – QuoteMedia (QMCI) – Is It Having Trouble With The Smaller Fish While Looking For A Big One?

Tuesday, March 31, 2020

QuoteMedia (QMCI)

Is It Having Trouble With The Smaller Fish While Looking For A Big One?

QuoteMedia, based in Fountain Hills, Arizona, provides cloud-based financial data, market news feeds, and financial software solutions.  Its customers include financial service companies, online brokerages, clearing firms, banks, media portals, public corporations and individual investors.  The company provides a single source solution providing products such as streaming quotes, charting, historical data, technical analysis, news and research.  Information can customized and provided to multiple platforms including terminals and mobile devices.

Michael Kupinski, DOR, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Uninspiring Q4. Revenues increased a moderate 4.3% to $2.97 million, a tad lighter than our $3.02 million estimate, or 6.1% growth. For the year, total company revenues increased 6.0%, a significant deceleration from full year 2018 revenue growth of 17.2%. Corporate and Individual Quotestream revenue weakness accounted for the muted revenue performance.

    Cash flow slightly better. Q4 cash flow, as measured by adjusted EBITDA, was $0.52 million, better than our…


    Click here to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Research – TherapeuticsMD Inc. (TXMD) – Not Unexpected: 2020 Guidance is Suspended

Monday, March 30, 2020

TherapeuticsMD Inc. (TXMD)

Not Unexpected: 2020 Guidance is Suspended

(current) TherapeuticsMD, Inc. is a women’s healthcare company focused on developing and commercializing products targeted exclusively for women. It manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins and cosmetics, under our vitaMedMD’ and BocaGreenMD’ brands. The company is currently developing advanced hormone therapy pharmaceutical products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. It is also evaluating various other potential indications for our hormone technology, including oral contraception, preterm birth, vulvar and vaginal atrophy, and premature ovarian failure.

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Business update. Today, TherapeuticsMD announced a business update driven by the impact of COVID-19 pandemic. We think the implemented model is coherent in these difficult and uncertain times for an early stage commercial company like TherapeuticsMD.

    Reduced cost and spending. The Company implemented measures to cut or defer more than $30M in annual spending including $10 million deferral in Q2 marketing spend for Annovera and Imvexxy and $20 million cut in other…



    Click here to get the full report.

This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Research dyadic international inc- dyai established another partnership in china

Monday, March 30, 2020

Dyadic International Inc. (DYAI)

Established Another Partnership in China

Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the industrially proven hyper productive engineered fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), named C1.
The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles (VLPs) and antigens, monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in development and manufacture of biopharmaceuticals. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic vaccines, drugs and other biologic products to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers, and improve access and cost to patients and the healthcare system, but most importantly save lives.

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Dyadic added another company to its partnership portfolio. Dyadic entered into a nonexclusive research collaboration with WuXi Biologics to evaluate the C1 technology in a cGMP facility and to perform experiments with the C1 cell lines for any other internal noncommercial purposes. WuXi Biologics is a China-headquartered biologics discovery, development, and manufacturing company. The current portfolio expanded to ten partnerships assessing the C1 platform in biologics manufacturing.

    What do these partnerships mean for Dyadic? The company implements a business model where the C1 expression system is being assessed in multiple biologic modalities (vaccines, gene therapy, antibodies, and others) by multiple partners (Sanofi, Zapi, Serum India, and others). By implementing this business model, Dyadic is keeping its cash burn at a minimum, while diversifying the C1’s portfolio and potentially increasing its probability of success. The company is also…



    Get the full report on Channelchek desktop.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Research – PDS Biotechnology (PDSB) – Well Funded to Advance Cancer Programs

Monday, March 30, 2020

PDS Biotechnology (PDSB)

Well Funded to Advance Cancer Programs

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is primarily engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

Cosme Ordonez, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

PDS Biotechnology F2019 Financial Results, Boosting Cash Position. After the close on Friday March 27, PDS Biotechnology announced financial results for F2019. The company reported a net loss of $6.9 mm compared to our estimate of $7.5 mm as our forecast included higher R&D and SG&A expenses. As of December 31, 2019, PDS reported cash and cash equivalents of $12.2 mm. In February, the company raised an additional $11.9 mm. We believe strengthened cash position allows management to advance its cancer clinical programs.

Business update highlights importance of Phase I results. PDS Biotechnology completed a Phase I clinical trial on the use of its lead drug PDS0101 for the treatment of cervical intraepithelial neoplasia (CIN). In the trial, the treatment elicited a potent anti-cancer immune response. 60% of treated patients showed regression of lesions. This year, the company plans to initiate several Phase II clinical trials evaluating PDS0101 for the treatment of…


Click here to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Research electrocore ecor gammacore received clearance for prevention of migraine

Monday, March 30, 2020

electroCore (ECOR)

gammaCore Received Clearance for Prevention of Migraine

electrocore Inc is a commercial-stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology and rheumatology. Its product gammaCore is FDA-cleared for the acute treatment of pain associated with migraine and episodic cluster headache in adults.

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Label expansion of gammaCore. electroCore announced the 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the label indication of gammaCore therapy to prevention of migraine in adult patients.

    The largest market among approved indications. gammaCore is now approved for the prevention and treatment of migraines and cluster headache in adults. We think this is a significant milestone for the company. Prevention of migraine represents the largest growth opportunity for gammaCore sales. Estimates indicate that migraine sales will grow to $6.5 billion by 2027, potentially tripling in size. The migraine prophylaxis market could nearly quadruple to…



    Get the full report on Channelchek desktop.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Research – Ely Gold Royalties (ELY:CA) – A Golden Opportunity to Invest in an Emerging Gold Royalty Company

Monday, March 30, 2020

Ely Gold Royalities (ELY:CA)

A Golden Opportunity to Invest in an Emerging Gold Royalty Company

Ely Gold Royalties Inc is an emerging royalty company with producing and development assets focused in Nevada and the Western US. It offers shareholders a low-risk leverage to the current price of gold and low-cost access to long-term gold royalties.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Initiating coverage. Ely Gold is an emerging gold royalty company with a growing asset portfolio that includes 43 royalties, including three that are producing. Thirty-three are deeded royalties, while 10 are on leased property. Additionally, the company has 19 properties optioned for sale to third parties that provide a source of revenue under option/sale agreements. Lastly, the company has 35 properties available for sale and/or option. Ely Gold has made several significant transactions during the past six months which are expected to accelerate revenue and cash flow growth beginning in 2020 and potentially support the initiation of a dividend in 2021. The company is well-capitalized to fund its growth initiatives.

    Attractive mining jurisdictions. The company’s projects are in favorable mining jurisdictions in the United States and Canada, including Nevada, Idaho and Quebec. Most of Ely’s properties are in Nevada, which ranked third among 76 mining jurisdictions in investment attractiveness in the 2019 Fraser Institute Annual Survey of…


    Click here to get the full report on Channelchek desktop.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Research – Dyadic International Inc. (DYAI) – Established Another Partnership in China

Monday, March 30, 2020

Dyadic International Inc. (DYAI)

Established Another Partnership in China

Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the industrially proven hyper productive engineered fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), named C1.
The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles (VLPs) and antigens, monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in development and manufacture of biopharmaceuticals. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic vaccines, drugs and other biologic products to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers, and improve access and cost to patients and the healthcare system, but most importantly save lives.

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Dyadic added another company to its partnership portfolio. Dyadic entered into a nonexclusive research collaboration with WuXi Biologics to evaluate the C1 technology in a cGMP facility and to perform experiments with the C1 cell lines for any other internal noncommercial purposes. WuXi Biologics is a China-headquartered biologics discovery, development, and manufacturing company. The current portfolio expanded to ten partnerships assessing the C1 platform in biologics manufacturing.

    What do these partnerships mean for Dyadic? The company implements a business model where the C1 expression system is being assessed in multiple biologic modalities (vaccines, gene therapy, antibodies, and others) by multiple partners (Sanofi, Zapi, Serum India, and others). By implementing this business model, Dyadic is keeping its cash burn at a minimum, while diversifying the C1’s portfolio and potentially increasing its probability of success. The company is also…



    Get the full report on Channelchek desktop.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Research pds biotechnology pdsb well funded to advance cancer programs

Monday, March 30, 2020

PDS Biotechnology (PDSB)

Well Funded to Advance Cancer Programs

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is primarily engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

Cosme Ordonez, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

PDS Biotechnology F2019 Financial Results, Boosting Cash Position. After the close on Friday March 27, PDS Biotechnology announced financial results for F2019. The company reported a net loss of $6.9 mm compared to our estimate of $7.5 mm as our forecast included higher R&D and SG&A expenses. As of December 31, 2019, PDS reported cash and cash equivalents of $12.2 mm. In February, the company raised an additional $11.9 mm. We believe strengthened cash position allows management to advance its cancer clinical programs.

Business update highlights importance of Phase I results. PDS Biotechnology completed a Phase I clinical trial on the use of its lead drug PDS0101 for the treatment of cervical intraepithelial neoplasia (CIN). In the trial, the treatment elicited a potent anti-cancer immune response. 60% of treated patients showed regression of lesions. This year, the company plans to initiate several Phase II clinical trials evaluating PDS0101 for the treatment of…


Click here to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Research ely gold royalties ely ca a golden opportunity to invest in an emerging gold royalty company

Monday, March 30, 2020

Ely Gold Royalities (ELY:CA)

A Golden Opportunity to Invest in an Emerging Gold Royalty Company

Ely Gold Royalties Inc is an emerging royalty company with producing and development assets focused in Nevada and the Western US. It offers shareholders a low-risk leverage to the current price of gold and low-cost access to long-term gold royalties.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Initiating coverage. Ely Gold is an emerging gold royalty company with a growing asset portfolio that includes 43 royalties, including three that are producing. Thirty-three are deeded royalties, while 10 are on leased property. Additionally, the company has 19 properties optioned for sale to third parties that provide a source of revenue under option/sale agreements. Lastly, the company has 35 properties available for sale and/or option. Ely Gold has made several significant transactions during the past six months which are expected to accelerate revenue and cash flow growth beginning in 2020 and potentially support the initiation of a dividend in 2021. The company is well-capitalized to fund its growth initiatives.

    Attractive mining jurisdictions. The company’s projects are in favorable mining jurisdictions in the United States and Canada, including Nevada, Idaho and Quebec. Most of Ely’s properties are in Nevada, which ranked third among 76 mining jurisdictions in investment attractiveness in the 2019 Fraser Institute Annual Survey of…


    Click here to get the full report on Channelchek desktop.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Research therapeuticsmd inc- txmd not unexpected 2020 guidance is suspended

Monday, March 30, 2020

TherapeuticsMD Inc. (TXMD)

Not Unexpected: 2020 Guidance is Suspended

(current) TherapeuticsMD, Inc. is a women’s healthcare company focused on developing and commercializing products targeted exclusively for women. It manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins and cosmetics, under our vitaMedMD’ and BocaGreenMD’ brands. The company is currently developing advanced hormone therapy pharmaceutical products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. It is also evaluating various other potential indications for our hormone technology, including oral contraception, preterm birth, vulvar and vaginal atrophy, and premature ovarian failure.

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Business update. Today, TherapeuticsMD announced a business update driven by the impact of COVID-19 pandemic. We think the implemented model is coherent in these difficult and uncertain times for an early stage commercial company like TherapeuticsMD.

    Reduced cost and spending. The Company implemented measures to cut or defer more than $30M in annual spending including $10 million deferral in Q2 marketing spend for Annovera and Imvexxy and $20 million cut in other…



    Click here to get the full report.

This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Research – electroCore (ECOR) – gammaCore Received Clearance for Prevention of Migraine

Monday, March 30, 2020

electroCore (ECOR)

gammaCore Received Clearance for Prevention of Migraine

electrocore Inc is a commercial-stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology and rheumatology. Its product gammaCore is FDA-cleared for the acute treatment of pain associated with migraine and episodic cluster headache in adults.

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Label expansion of gammaCore. electroCore announced the 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the label indication of gammaCore therapy to prevention of migraine in adult patients.

    The largest market among approved indications. gammaCore is now approved for the prevention and treatment of migraines and cluster headache in adults. We think this is a significant milestone for the company. Prevention of migraine represents the largest growth opportunity for gammaCore sales. Estimates indicate that migraine sales will grow to $6.5 billion by 2027, potentially tripling in size. The migraine prophylaxis market could nearly quadruple to…



    Get the full report on Channelchek desktop.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.